Results 121 to 130 of about 2,262 (198)

ADNP regulates chromatin architecture and lineage fidelity during neural differentiation. [PDF]

PLoS Genet
Wulfridge P, Rell N, Doherty J, Fang KC, Lynskey ML, Sarma K.   +5 more
europepmc   +1 more source

Network pharmacology and molecular docking reveal antiviral mechanisms of silver nanoparticles synthesized by Oscillatoria sp. against HCV pathogenesis. [PDF]

Sci Rep
Azmy L, Al-Olayan E, Abdelhamid MAA, Ibraheem IBM, Zayed A, Gheda SF, Youssif KA, Abou-Zied HA, Abdelmohsen UR, Pack SP, Khalifa HO, Elsayed KNM.   +11 more
europepmc   +1 more source

Exploring drug repurposing for monkeypox virus: A structural and computational approach. [PDF]

J Taibah Univ Med Sci
Gul S, Akhtar F, Rehman I, Shah M, Rashid U, Rauf A.   +5 more
europepmc   +1 more source

A bacteria-based search for drugs against avian and swine flu yields a potent and resistance-resilient channel blocker. [PDF]

Proc Natl Acad Sci U S A
Lahiri H, Israeli E, Krugliak M, Basu K, Britan-Rosich Y, Ravins Yaish T, Arkin IT.   +6 more
europepmc   +1 more source

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects [PDF]

, 2017
Tushar S. Garimella, Xiaolu Tao, Karen Sims, Yi‐Ting Chang, Jignasa Rana, Elsa Myers, Megan Wind‐Rotolo, Rahul Bhatnagar, Timothy Eley, Frank P. LaCreta, Malaz A. Abutarif   +10 more
openalex   +1 more source

EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1

AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1. METHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016. We followed them
OHSHIMA, Shigetoshi, Miura, Masato, KURAMITSU, Tomoyuki, FUJISHIMA, Yuukou, WATANABE, Daisuke, NAKANE, Kunio, Goto, Mitsuo, AJIMINE, Takuma, YAGISAWA, Hitoshi, NAKAJIMA, Kou, GOTO, Takashi, IIJIMA, Katsunori, HOSHINO, Takao, Inomata, Masaaki, KOMATSU, Masafumi, FUNAOKA, Masato, Segawa, Daisuke   +16 more
core  

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs). [PDF]

Viruses
Di Marco L, Cannova S, Ferrigno E, Landro G, Nonni R, Mantia C, Cartabellotta F, Calvaruso V, Di Marco V.   +8 more
europepmc   +1 more source

Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis. [PDF]

Sci Rep
Mawatari S, Tanoue S, Kumagai K, Oda K, Toyodome A, Sakae H, Fujisaki K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Tabu K, Ijuin S, Hori T, Tamai T, Moriuchi A, Kanmura S, Ido A.   +17 more
europepmc   +1 more source

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors. [PDF]

Sci Rep
Toyodome A, Mawatari S, Eguchi H, Takeda M, Kumagai K, Taniyama O, Ijuin S, Sakae H, Tabu K, Oda K, Ikeda M, Ido A.   +11 more
europepmc   +1 more source

Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study. [PDF]

PLoS One
Park YJ, Yi KY, Woo HY, Heo J, Song GA.
europepmc   +1 more source